Monaco Asset Management SAM Has $727,000 Holdings in Nektar Therapeutics (NASDAQ:NKTR)

Monaco Asset Management SAM trimmed its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 47.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,068,899 shares of the biopharmaceutical company's stock after selling 963,969 shares during the period. Monaco Asset Management SAM owned 0.57% of Nektar Therapeutics worth $727,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NKTR. Two Sigma Securities LLC lifted its stake in Nektar Therapeutics by 56.3% during the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 9,958 shares during the last quarter. Harvest Investment Services LLC acquired a new stake in Nektar Therapeutics during the fourth quarter valued at approximately $27,000. US Asset Management LLC acquired a new stake in Nektar Therapeutics during the fourth quarter valued at approximately $31,000. ProShare Advisors LLC lifted its stake in Nektar Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 50,277 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 16,543 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Nektar Therapeutics during the first quarter valued at approximately $41,000. 75.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on NKTR shares. Jefferies Financial Group upgraded shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and boosted their price target for the company from $15.00 to $30.00 in a report on Friday, April 11th. HC Wainwright upped their price objective on shares of Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a report on Tuesday, June 24th. Wall Street Zen downgraded shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday, May 14th. BTIG Research upped their price objective on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, June 24th. Finally, B. Riley upped their price objective on shares of Nektar Therapeutics from $60.00 to $85.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $88.33.

Nektar Therapeutics Stock Up 5.9%

Nektar Therapeutics stock traded up $1.28 during mid-day trading on Friday, reaching $22.96. The company had a trading volume of 504,502 shares, compared to its average volume of 869,333. Nektar Therapeutics has a 52 week low of $6.45 and a 52 week high of $37.38. The firm has a market cap of $284.93 million, a price-to-earnings ratio of -2.39 and a beta of 0.94. The company has a 50 day moving average of $18.18 and a 200-day moving average of $13.76.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). The business had revenue of $10.46 million during the quarter, compared to analyst estimates of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. During the same quarter in the prior year, the company posted ($2.70) EPS. On average, analysts predict that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.